Opioids in Nursing Home Residents



Presented by: Dr. Swati Gaur, MD, MBA, CMD, AGSF







Jennifer Massey, PharmD

AHS TECHNICAL ADVISOR, PHARMACY SERVICES

Jennifer has 15 years of health care experience, including clinical pharmacy in the acute care hospital setting and various roles at Alliant Health Solutions working on the CMS contract for the Quality Innovation Network-Quality Improvement Organization (QIN-QIO).

She currently serves as the subject matter expert for opioids and adverse drug events for HQIC.


Contact: <u>Jennifer.Massey@allianthealth.org</u>



Dr. Swati Gaur, MD, MBA, CMD, AGSF

MEDICAL DIRECTOR, POST ACUTE CARE NORTHEAST GEORGIA HEALTH SYSTEM

Dr. Swati Gaur is the medical director of New Horizons Nursing Facilities with the Northeast Georgia Health System. She is also the CEO of Care Advances Through Technology, a technology innovation company. In addition, she is on the EMR transition and implementation team for the health system, providing direction to EMR entity adapt to the LTC environment. She also consulted with post-acute long-term care companies to optimize medical services into PALTC facilities, integrate medical directors and clinicians into the QAPI framework and creates frameworks of interdisciplinary work in the organization. She established the Palliative Care service line at the Northeast Georgia Health System. She also is an attending physician in several nursing facilities. Prior to that, Dr. Gaur was a medical director at the LTC in Carl Vinson VA Medical Center and a member of the G&EC for VISN 7.



Objectives

- Assessing pain and need for opioids in long-term care resident
- Anticipating and proactively managing opioid-related side effects
- Examining alternate modalities for pain control
- Discussing the role of the interdisciplinary team in opioid management




Assessing Pain and Need for Opioids in Long-Term Care Resident

- A 96-year-old woman fell in the nursing home while transferring from a chair to the bed and hit her left shoulder. The x-ray did not show a fracture.
- Three days later, the staff reported that she had stopped getting out of bed, and her appetite had steadily declined to where she's only eating 25% of her meals.
- A meeting was held with her son, who was appraised of the situation, and he
 decided not to transfer his mom to the hospital.



Is There an Association Between Pain and Delirium?



https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201828/




Optimal Length of Treatment

Procedure	Optimal length in days
General surgical	7
Women's health	10
Musculoskeletal	14

https://pubmed.ncbi.nlm.nih.gov/28973092/#:~:text=In%20practice%2C%20the%20optimal%20leng th,15%20days%20for%20musculoskeletal%20procedures



Approach to Acute Pain in LTC






Assessing Pain and Need for Opioids in Long-Term Care Resident

- A 78-year-old male was admitted with MS Contin 40mg BID and Dilaudid 2 mg every four hours as needed. Staff report that he's irritable and is demanding no change in medication.
- He's also on Xanax 1 mg BID and Neurontin 800mg Q12H.
- On further history, he lost his spouse, lives alone and had recently been approached about cutting down his meds. He also has short-term memory loss.
- He has a history of overdose.



Mortality and Concurrent Use of Opioids and Hypnotics in Older Patients: A Retrospective Cohort Study

Wayne A. Ray et al July 15, 2021



https://doi.org/10.1371/journal.pmed.1003709




Managing Opioid-Related Side Effects

Opioid-induced constipation (OIC) Opioid-induced bowel dysfunction (OIBD)

- 4-6/10 will have it
- Slow peristalsis- increase in fluid absorption hard stool and constipation
- Start laxative proactively
- Never use psyllium

Meds	Typical cost
Senna	\$10/100 pills
Polyethylene glycol	\$10/100 gm of powder
Relistor	\$430/15 pills
Amitiza	\$470/60 pills






https://www.degruyter.com/document/doi/10.1016/j.sjpain.2015.12.005/html




Examining Alternate Modalities for Pain Control



Local pain control - Capsaicin





Use of physical therapy and subsequent use of opioids

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC780 8685/



Adjuvant Therapies

Gabapentin

- Used for opioid-sparing effects postoperatively (new)
- Most effective in neuropathic pain
- Needs adjusted for CrCl
- Can cause Hypotension, sedation

Muscle relaxant

- Used as a part of multimodal pain management perioperatively
- Continued use can cause falls, delirium
- Increase use with concurrent use of opioids



Opioid stewardship – right time, right dose, right duration

Empower your IDT consultant pharmacist, nursing, therapists

Empower staff with education and tools

Make it a part of QAPI

PAR(patient at risk) Meeting



Questions?





Nursing Home and Partnership for Community Health:

CMS 12th SOW GOALS



OPIOID UTILIZATION AND MISUSE

Promote opioid best practices

Reduce opioid adverse drug events in all settings



PATIENT SAFETY

Reduce hospitalizations due to c. diff

Reduce adverse drug events

Reduce facility acquired infections



CHRONIC DISEASE SELF-MANAGEMENT

Increase instances of adequately diagnosed and controlled hypertension

Increase use of cardiac rehabilitation programs

Reduce instances of uncontrolled diabetes

Identify patients at highrisk for kidney disease and improve outcomes



CARE COORDINATION

Convene community coalitions

Reduce avoidable readmissions, admissions to hospitals and preventable emergency department visits

Identify and promote optimal care for super utilizers



COVID-19

Support nursing homes by establishing a safe visitor policy and cohort plan

Provide virtual events to support infection control and prevention

Support nursing homes and community coalitions with emergency preparedness plans



IMMUNIZATION

Increase influenza, pneumococcal, and COVID-19 vaccination rates



TRAINING

Encourage completion of infection control and prevention trainings by front line clinical and management staff



Scan the QR codes or Click the Links to Complete the Assessments!

CMS requested Alliant Health Solutions, your QIN-QIO, to work with select nursing homes to understand emerging healthcare needs in nursing homes. Alliant Health Solutions is engaging nursing home leadership on each of these key areas to ensure plans are in place to achieve and maintain health quality and equity!

Please scan the QR codes below and complete the assessments.



COVID-19

Support nursing homes by establishing a safe visitor policy and cohort plan

Provide virtual events to support infection control and prevention

Support nursing homes and community coalitions with emergency preparedness plans Nursing Home
Emergency
Preparedness
Program (NH EPP)
Self-Assessment





TRAINING

Encourage completion of infection control and prevention trainings by front line clinical and management staff Nursing Home Infection Prevention (NHIP) Initiative Training Assessment





COVID-19

Support nursing homes by establishing a safe visitor policy and cohort plan

Provide virtual events to support infection control and prevention

Support nursing homes and community coalitions with emergency preparedness plans Nursing Home Safe Visitor Policy and Cohorting Plan Verification



https://bit.ly/AHS_NHEPPAssessment

https://bit.ly/NHIPAssessment

https://bit.ly/SafeVisitorVerification



Save the Date

Register for our next session:

Opioids in Nursing Home to Home Transitions

- Date: Wednesday, Nov. 9, 2022
- Time: 2-2:30 p.m. ET
- Hosted by: Madison McRainey, PhamD

Registration link: https://bit.ly/NHOpioidSeries_Nov9







Georgia, Kentucky, North Carolina and Tennessee







Making Health Care Better Together ALABAMA · FLORIDA · GEORGIA · KENTUCKY · LOUISIANA · NORTH CAROLINA · TENNESSE





Alliant Health Solutions





This material was prepared by Alliant Health Solutions, a Quality Innovation Network – Quality Improvement Organization (QIN – QIO) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication No. 12SOW-AHS-QIN-QIO TO1-NH--2639-09/27/22

